CDTX Quote, Financials, Valuation and Earnings

iBio has a net margin of -30201.66% compared to Cidara Therapeutics's net margin of -4444.57%. Cidara Therapeutics's return on equity of -443.37% beat iBio's return on equity of -148.3%.

Cidara Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 31.25%. On the other hand iBio has an analysts' consensus of $3.60 which suggests that it could grow by 41.18%. Given that iBio has higher upside potential than Cidara Therapeutics, analysts believe iBio is more attractive than Cidara Therapeutics.

Cidara Therapeutics has a beta of 0.983, which suggesting that the stock is 1.698% less volatile than S&P 500. In comparison iBio has a beta of -3.266, suggesting its less volatile than the S&P 500 by 426.584%.

Cidara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Cidara Therapeutics quarterly revenues are $302K, which are larger than iBio quarterly revenues of $175K. Cidara Therapeutics's net income of -$16M is lower than iBio's net income of -$4M. Notably, Cidara Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics is 1.97x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -30201.66% compared to Cidara Therapeutics's net margin of -49.65%. Cidara Therapeutics's return on equity of -443.37% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cidara Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 31.25%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than Cidara Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Cidara Therapeutics.

Cidara Therapeutics has a beta of 0.983, which suggesting that the stock is 1.698% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Cidara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cidara Therapeutics quarterly revenues are $302K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cidara Therapeutics's net income of -$16M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Cidara Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics is 1.97x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -30201.66% compared to Cidara Therapeutics's net margin of -2357.27%. Cidara Therapeutics's return on equity of -443.37% beat Palatin Technologies's return on equity of --.

Cidara Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 31.25%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1404.43%. Given that Palatin Technologies has higher upside potential than Cidara Therapeutics, analysts believe Palatin Technologies is more attractive than Cidara Therapeutics.

Cidara Therapeutics has a beta of 0.983, which suggesting that the stock is 1.698% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Cidara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Cidara Therapeutics quarterly revenues are $302K, which are smaller than Palatin Technologies quarterly revenues of $350K. Cidara Therapeutics's net income of -$16M is lower than Palatin Technologies's net income of -$7.8M. Notably, Cidara Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics is 1.97x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology has a net margin of -30201.66% compared to Cidara Therapeutics's net margin of -20.17%. Cidara Therapeutics's return on equity of -443.37% beat Pyxis Oncology's return on equity of --.

Cidara Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 31.25%. On the other hand Pyxis Oncology has an analysts' consensus of $8.83 which suggests that it could grow by 469.89%. Given that Pyxis Oncology has higher upside potential than Cidara Therapeutics, analysts believe Pyxis Oncology is more attractive than Cidara Therapeutics.

Cidara Therapeutics has a beta of 0.983, which suggesting that the stock is 1.698% less volatile than S&P 500. In comparison Pyxis Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cidara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics pays -- of its earnings as a dividend. Pyxis Oncology pays out -- of its earnings as a dividend.

Cidara Therapeutics quarterly revenues are $302K, which are smaller than Pyxis Oncology quarterly revenues of $16.1M. Cidara Therapeutics's net income of -$16M is higher than Pyxis Oncology's net income of -$21.2M. Notably, Cidara Therapeutics's price-to-earnings ratio is -- while Pyxis Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics is 1.97x versus -- for Pyxis Oncology. Usually stocks with elevated PS ratios are considered overvalued.